Literature DB >> 29307892

Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.

Christoph Wanner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29307892     DOI： 10.1038/nrneph.2017.182

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  8 in total

1.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.

Authors:  David Z I Cherney; Bernard Zinman; Silvio E Inzucchi; Audrey Koitka-Weber; Michaela Mattheus; Maximilian von Eynatten; Christoph Wanner
Journal:  Lancet Diabetes Endocrinol       Date:  2017-06-27       Impact factor: 32.069

Review 3.  Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.

Authors:  Volker Vallon; Scott C Thomson
Journal:  Diabetologia       Date:  2016-11-22       Impact factor: 10.122

4.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

5.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

6.  Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.

Authors:  Christoph Wanner; John M Lachin; Silvio E Inzucchi; David Fitchett; Michaela Mattheus; Jyothis George; Hans J Woerle; Uli C Broedl; Maximilian von Eynatten; Bernard Zinman
Journal:  Circulation       Date:  2017-09-13       Impact factor: 29.690

7.  Liraglutide and Renal Outcomes in Type 2 Diabetes.

Authors:  Johannes F E Mann; David D Ørsted; Kirstine Brown-Frandsen; Steven P Marso; Neil R Poulter; Søren Rasmussen; Karen Tornøe; Bernard Zinman; John B Buse
Journal:  N Engl J Med       Date:  2017-08-31       Impact factor: 91.245

8.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245
  8 in total
  1 in total

1.  Variability in the incidence of renal replacement therapy over time in Western industrialized countries: A retrospective registry analysis.

Authors:  Vicky De Meyer; Daniel Abramowicz; Johan De Meester; Fréderic Collart; Jean-Louis Bosmans; Wilfried Cools; Karl Martin Wissing
Journal:  PLoS One       Date:  2020-06-25       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.